The US Food and Drug Administration (FDA) has released draft guidance to assist sponsors with incorporating dose banding information in drug labeling for ready-to-use containers in new drug applications (NDAs), biologics license applications (BLA) or supplements to those applications.   Dose banding refers to dosing a drug product based on weight or body surface area (BSA), and labeling can include a range of different strengths.   This approach reduces “signific...